Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: A randomized, double-blind, placebo-controlled study

American Journal of Gastroenterology

Volumn 107, Issue 11, 2012, Pages 1662-1667

  Viazis, Nikos ^a   Keyoglou, Anastasia ^a   Kanellopoulos, Alexandros K ^b   Karamanolis, George ^c   Vlachogiannakos, John ^d   Triantafyllou, Konstantinos ^c   Ladas, Spiros D ^d   Karamanolis, Dimitrios G ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESOPHAGUS DISEASE; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HUMAN; HYPERSENSITIVE ESOPHAGUS; MAJOR CLINICAL STUDY; MALE; PH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN;

ADOLESCENT; ADULT; AGED; CITALOPRAM; DOUBLE-BLIND METHOD; ESOPHAGEAL PH MONITORING; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROTON PUMP INHIBITORS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84869498894     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.179     Document Type: Article

References (30)

1. Kahrilas P. Gastroesophageal reflux disease. JAMA 1996; 276: 983-8. (Pubitemid 26318229)
2. Lagergren J, Bergestrom R, Lindgren A et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31. (Pubitemid 29142625)
3. Hungin A, Hill C, Raghunath A. Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia. Aliment Pharmacol Ther 2009; 30: 331-42.
4. Malfertheiner P, Fass R, Quigley E et al. Review article: from gastrin to gastro-oesophageal reflux disease-a century of acid suppression. Aliment Pharmacol Ther 2006; 23: 683-90. (Pubitemid 43344587)
5. Mainie I, Tutuian R, Shay S et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance pH monitoring. Gut 2006; 55: 1398-402. (Pubitemid 44476780)
6. Vela M. Non-acid reflux: detection by multichannel intraluminal impedance and pH, Clinical significance and management. Am J Gastroenterol 2009; 104: 277-80.
7. Fass R, Fennerty M, Vakil N. Non-erosive reflux disease (NERD)-current concepts and dilemmas. Am J Gastroenterol 2001; 96: 303-14.
8. Peghini P, Katz P, Castell D. Imipramine decreases oesophageal pain perception in human male volunteers. Gut 1998; 42: 807-13. (Pubitemid 28277221)
9. Cannon R, Quyyumi A, Mincemoyer R et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994; 330: 1411-9.
10. Clouse R, Lustman P, Eckert T et al. Low dose trazodone for symptomatic patients with esophageal contraction abnormalities. Gastroenterology 1998; 92: 1027-36.
11. Handa M, Mine K, Yamamoto H et al. Antidepressant treatment of patients with diff use esophageal spasm: a psychosomatic approach. J Clin Gastroenterol 1999; 28: 228-32. (Pubitemid 29141102)
12. Vakil N, van Zanten S, Kahrilas P, et al., and the Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
13. Zentilin P, Liritano E, Dulbecco P et al. Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a Mediterranean diet. Dig Liv Dis 2006; 38: 226-32. (Pubitemid 44356183)
14. Srinivasan R, Vela M, Katz P et al. Oesophageal function testing using multichannel intraluminal impedance. Am J Physiol Gastrointest Liver Physiol 2001; 280: G457-62.
15. Sifrim D, Castell D, Dent J et al. Gastro-esophageal reflux monitoring: review and consensus report on detection and definition of acid, non-acid and gas reflux. Gut 2004; 53: 1024-31. (Pubitemid 38824163)
16. Mattox H, Richter J. Prolonged ambulatory esophageal pH monitoring in the evaluation of gastroesophageal reflux disease. Am J Med 1990; 89: 345-56. (Pubitemid 20323262)
17. Pace F, Annese V, Ceccatelli P et al. Ambulatory oesophageal pH-metry. Position paper of the working team on oesophageal pHmetry by the GISMAD (Gruppo Italiano di Studio sulla Motilita dell' Apparato Digerente). Dig Liver Dis 2000; 32: 357-64. (Pubitemid 30445076)
18. Bredenoord A, Weusten B, Smout A. Symptom association analysis in ambulatory gastro-oesophageal reflux monitoring. Gut 2005; 54: 1810-7. (Pubitemid 41697683)
19. Savarino E, Zentilin P, Tutuian R et al. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 2008; 103: 2685-93.
20. Lind T, Havelund T, Carlsson R et al. Heartburn without oesophagitis: effi-cacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-9. (Pubitemid 27433659)
21. Dent J, Brun J, Fendrick A et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999; 44: S1-S16. (Pubitemid 29151973)
22. Lee K, Kwon H, Cheong J et al. Demographic, clinical and psychological characteristics of the heartburn groups classified using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group. Digestion 2009; 79: 131-6.
23. Fass R, Tougas G. Functional heartburn: the stimulus, the pain and the brain. Gut 2002; 51: 885-92. (Pubitemid 35408615)
24. Hong S, Vaezi M. Gastroesophageal reflux monitoring: pH (catheter and capsule) and impedance. Gastrointest Endoscopy Clin N Am 2009; 19: 1-22.
25. Savarino E, Pohl D, Zentilin P et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 2009; 58: 1185-91.
26. Broekaert D, Fischler B, Sifrim D et al. Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a doubleblind, placebo-controlled study. Aliment Pharmacol Ther 2006; 23: 365-70. (Pubitemid 43382016)
27. Hollerbach S, Bulat R, May A et al. Abnormal cerebral processing of oesophageal stimuli in patients with noncardiac chest pain (NCCP). Neurogastroenterol Mot 2000; 12: 555-65. (Pubitemid 32001454)
28. Kim D, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000; 95: 2698-709.
29. Gershon M, Tack J. The serotonin signalling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397-414. (Pubitemid 46127672)
30. Tack J, Broekaert D, Coulie B et al. Influence of the selective serotonin reuptake inhibitor paroxetine on gastric sensorimotor function in humans. Aliment Pharmacol Ther 2003; 17: 603-8. (Pubitemid 36384820)